首页> 美国卫生研究院文献>Neuro-Oncology >ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA

【2h】

ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA

机译：ATCT-22NRG ONCOLOGY / RTOG 1122：II期双盲放置控制的贝伐单抗治疗或复发性胶质母细胞瘤或胶质肉瘤患者的AMG 386的双盲放药控制研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Neuro-Oncology
作者
Eudocia Q. Lee; Peixin Zhang; Patrick Y. Wen; Elizabeth R. Gerstner; David A. Reardon; Ken Aldape; John F. de Groot; Kevin S. Choe; Jeffrey J. Raizer; Lyndon J. Kim; Steven J. Chmura; H. Ian Robins; Jennifer Connelly; James Battiste; John Villano; Naveed Wagle; Ryan T. Merrell; Merideth Wendland; Minesh P. Mehta;
展开▼
作者单位

展开▼
年(卷),期 2015(17),Suppl 5
年度 2015
页码 v6
总页数 1
原文格式 PDF
正文语种
中图分类神经病学;肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Randomized Phase II Trial of Re-Irradiation and Concurrent Bevacizumab versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma (NRG Oncology/RTOG 1205): Initial Outcomes and RT Plan Quality Report [J] . Tsien C., Pugh S., Dicker A. P., International Journal of Radiation Oncology, Biology, Physics . 2019,第1Suppla期

机译：单独的再辐射和同时贝伐单抗的随机期II试验单独单独用作复发胶质母细胞瘤的治疗（NRG肿瘤学/ RTOG 1205）：初始结果和RT计划质量报告
2. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer [J] . KarlanB.Y., OzaA.M., RichardsonG.E., Journal of Clinical Oncology . 2012,第4期

机译：复发性卵巢癌患者AMG 386联合每周紫杉醇的随机，双盲，安慰剂对照II期研究
3. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O-6-Methylguanine-DNA Methyltransferase Biomarker Analyses [J] . Cloughesy Timothy, Finocchiaro Gaetano, Belda-Iniesta Cristobal, Journal of Clinical Oncology . 2017,第3期

机译：随机，双盲，安慰剂控制，onartuzumab加贝伐单抗的多中心研究与复发性胶质母细胞瘤患者中的安慰剂和贝伐单抗：疗效，安全性和肝细胞生长因子和O-6-甲基胍丁胺-DNA甲基转移酶生物标志物分析
4. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
5. ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA [O] . Christina Tsien, Stephanie Pugh, adam Dicker, 2019

机译：ACTR-32。 NRG肿瘤RTOG 1205：随机相位II试验并发贝伐单抗和重新照射与单独的贝伐单抗作为反复胶质母细胞瘤的治疗
6. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses [O] . Cloughesy, Timothy, Finocchiaro, Gaetano, Belda-Iniesta, Cristóbal, 2017

机译：复发性胶质母细胞瘤患者中Onartuzumab加Bevacizumab与安慰剂加Bevacizumab的随机，双盲，安慰剂对照多中心II期研究：有效性，安全性和肝细胞生长因子以及O（6）-甲基鸟嘌呤-DNA甲基转移酶生物标志物分析

ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA

著录项

引文网络

相似文献

相关主题

期刊订阅